Summary: Lauren Silva of Forbes outlines recent psychedelic studies, interviews Michael Mithoefer, M.D., of MAPS Public Benefit Corporation (MAPS PBC), and emphasizes how “the FDA granted MDMA a breakthrough therapy designation for the treatment of post traumatic stress disorder (PTSD) to MAPS.”
“While there are many challenges ahead for psychedelic therapy, the plethora of discoveries and advances that are currently happening offer both trauma-informed medicine and individuals dealing with difficult mental health challenges hope for a more fully embodied life,” writes Silva.
